Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases
Research peptides are supplied in lyophilised (freeze-dried) form a dry powder created by removing all moisture from the peptide solution under vacuum
There are no theoretical oncologic concerns
As of June 2025, the branded version of liraglutide, Saxenda, generated $165 million in annual sales alone, and the market for GLP-1s could be set to hit over $126 billion in sales by 2029
Barrier support: In epithelial models, KPV has shown an ability to support tight junction integrity and promote mucosal repair, adding a structural dimension to its anti inflammatory profile
Should a patient be unable to tolerate GI adverse events, a lower dose or alternative GLP-1 receptor agonist can be considered